Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
15.9M
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
290K
-
Shares change
-
+94.7K
-
Total reported value, excl. options
-
$292K
-
Value change
-
+$95.7K
-
Number of buys
-
6
-
Number of sells
-
-4
-
Price
-
$1.01
Significant Holders of ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) as of Q4 2024
15 filings reported holding ADIL - ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share as of Q4 2024.
ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 290K shares
of 15.9M outstanding shares and own 1.82% of the company stock.
Largest 10 shareholders include GEODE CAPITAL MANAGEMENT, LLC (61.8K shares), CITADEL ADVISORS LLC (54.5K shares), Manchester Capital Management LLC (48.1K shares), RENAISSANCE TECHNOLOGIES LLC (47.6K shares), BlackRock, Inc. (27.8K shares), Cambridge Investment Research Advisors, Inc. (27K shares), UBS Group AG (21K shares), SBI Securities Co., Ltd. (937 shares), Tower Research Capital LLC (TRC) (638 shares), and WELLS FARGO & COMPANY/MN (160 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.